STT - 3 Drug Stocks That Could Soar in 2020
Many generic drug makers began the year with a strong start after a dismal performance in 2019. The recent market plunge from the COVID-19 pandemic caused many pharmaceutical stocks to lose decent portions of their market values. Despite a broad market recovery, some of these stocks are still selling at bargain prices and could potentially be lucrative over the long term.
There are three small-cap and mid-cap generic drug stocks that are about to soar in 2020 and beyond. Each stock has a unique catalyst that will drive its stock higher through a variety of scenarios including a potential drug approval, formation of a new company, and market exclusivity in a large health space.
Let's take a look.